HF

IMAG

EP

CHFS

CLINICAL CARDIOLOGY

TRAINEE

GUIDELINES

Guidelines

CCS/CHFS JOINT POSITION STATEMENT ON THE EVALUATION AND MANAGEMENT OF PATIENTS WITH CARDIAC AMYLOIDOSIS

Presenter(s)

• 

  Margot Davis, MD SM FRCPC

  Assistant Professor
• Nowell F.

  Nowell Fine, MD SM PRCPC

  Director of Echocardiography, Heart Failure Cardiologist
  University of Calgary
• 

  Kim Anderson, MD, FRCPC

  Cardiologist, QEII-Halifax Infirmary

Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is therefore increasingly important for clinicians providing care for patients with cardiovascular disease to recognize the signs and symptoms of cardiac amyloidosis, understand effective strategies for diagnosis, and be aware of important management advances. The Canadian Cardiovascular Society/Canadian Heart Failure Society Position Statement provides evidence based recommendations supporting the early recognition, and optimal diagnostic approach and management strategies for patients with cardiac amyloidosis.

In this workshop session, members of the CCS/CHFS Amyloidosis panel will present key messages from the 2019 statement to highlight new evidence. Members will use example cases to discuss:
1. the symptomatic management of heart failure and other cardiovascular complications such as arrhythmia,
2. risk stratification and follow-up surveillance,
3. use of ATTR disease modifying therapies, and
4. optimal clinical care settings for patients with this complex multisystem disease.

Target Audience(s):

General: All cardiovascular (clinical and research) health professionals
Clinical cardiologists
Echocardiologists
Electrophysiologists
Heart failure specialists
Internists
Magnetic imaging specialist
Nuclear and CT imaging specialist
Trainee (clinical)

Learning Objectives

At the conclusion of this session, participants will be able to:

• identify effective strategies for the clinical recognition and diagnosis of cardiac amyloidosis;
• examine the use of ATTR disease modifying therapies; and
• discuss clinical care settings for optimal management of this complex disease.